and results it you Sue call joining. clinical I our of accomplishments everyone thank will we the program, for Q&A. the recent review a review financial then our development upcoming with will and up will milestones. for and open begin you Thank
metastatic November, cancer. Phase our ASPIRE of III the enrolled with our Starting patient program, we pancreatic Europe in first treatment first-line for in in our global trial clinical
to evaluate in SBP-XXX reminder, a or patients randomized, adenocarcinoma. pancreatic ASPIRE double-blind, As ivospemin metastatic ductal is trial a combination clinical and with with placebo-controlled in gemcitabine nab-paclitaxel global
in to up in our we approval trial just highly enrollment excited the really regulatory Europe first Italy. opening ramp have continue underway European sites after as is are to trial. We Having encouraging had the for patients enrolled receiving of recently
and enrollment Korea. just our global South continue last patient enrolled in first week We
and this full the country the on we to as aim of the ASPIRE on complement year. by middle have for site of the initiation trial focused sites are We board
continue are few Korea, to deliver enrollment approximately pancreatic advance with throughout encouraging deadly on States, South initiation as focus sites a Korea to planned United is underway options. we the effective we XX With continuing a disease the ultimately more cancer, and treatment treatment for South Having also to site trial. Australia Europe,
The trial primary the survival. endpoint patients is be approximately XXX size sample and will overall
We with take interim as the will in survival overall use complete analysis for It for enrollment early still well. analysis anticipated XX the interim is months approximately to XXXX. available
of well interim The optimal merits resource continuing us to as as assess analysis allows study, utilization. ensure to the the
We from forward expected are excited over in analysis one as little to have towards move these recent the we a interim year approvals now.
On a issued Orphan medicinal the designation related adoption with Products metastatic nab-paclitaxel combination product January, note, has with for of European pancreatic as ductal the or the Agency an implementing decision Medicinal relating Committee commission and in in SBP-XXX gemcitabine in of patients orphan to Medicines ivospemin, EMA adenocarcinoma.
future. orphan continue for the metastatic be within with of as the an status the potential may EU is designation patients drug The an trial ASPIRE pancreatic cancer to achievement advance the this option first-line global with in that important we
XX,XXX affects the for drug designation orphan the The EU. issued in available based five designation chronically Commission that European in the companies is by is than the Union to Committee fewer Products. threatening persons EMA’s Orphan on positive Orphan developing European Medicinal the for condition by debilitating or treatments granted EMA in opinion life
centralized assistance approval, marketing for Orphan phase, reduced XX-year may Designation EMA’s and qualify EU after and fees a during from exclusivity authorization. product financial incentives, access product criteria the protocol meet including of the and EMA in the that development market Medicines period regulatory to
licensing trial anticipated partner, half of funded second with FAP, is XXXX polyposis adenomatous to begin familial the our to and the or registration in by is Flynpovi One-Two Turning Therapeutics.
ensure to alignment One-Two the working all are commences. trial trial FDA with aspects with on before the We of the key closely
anticipate trial and in outside authorities of the to utilize retain we regarding registration we for the of Flynpovi the U.S. the advice rights the trial the As clinical that will utilization Europe. sites approval European European seek will from we and Canada,
Phase a As agent the gastrointestinal or study III evaluating showed for either reminder, risk surgery Eflornithine group. a in alone prior the need versus Flynpovi Sulindac and XXX% reduction lower in
focus approved lower FAP, of the As explaining GI there to a group be drug treatment new are currently trial. is registration and data is a no for of this the intended therapies
partnership Lastly, III recurrence primary in Eflornithine colon Phase adenomas Sulindac double-blind, prevent we Stage rectal of Again, or of second X placebo-controlled to cancer. combination of to high also risk cancers ongoing with with an in and and X the patients have trial One-Two Flynpovi. colorectal
is This the as Institute by Southwest is a look of the or Oncology with in Cancer known half XXXX. trial, forward as NCI, the National in the funded also trial SWOG first analysis we to known collaboration the PACES and futility Group
studies. II Phase to Moving
trial trial Group This funded ongoing through Children’s COG relapsed/refractory utilizing or NCI. neuroblastoma, an is the Eflornithine is and there First, in Oncology sachets. the
tablet Indiana evaluate the X of Type also start research study funded by and global Medicine for University double-blind, Phase the II School announced We diabetes X in leading of diabetes JDRF, onset Eflornithine recent advocacy randomized Type our and to collaboration organization. with
Phase be to eligibility Type at X onset patients XX United the will expects trial Medicine six of for School patients in recent clinical with approximately the enroll II University centers diabetes. Study States. Indiana in
will followed tablets placebo milligram at randomized square period X,XXX orally or to meter food Participants assess dose daily a a six-month months of be administered six per Eflornithine washout X:X durability over by to twice with response.
placebo or the mean C-peptide at curve log a treatment mean determine to the using objective AUC, of the the six-month end period. X-hour primary between The will and difference treated under area be
simulated, include months excuse me, nine of and months at fasting and biomarker content simulated three Secondary and cell objectives polyamine XX C-peptide C-peptide a urine will the proinsulin ratio, AUC, timepoints.. stress beta months,
Type which Medicine the global pleased begun for for life Eflornithine Phase is JDRF, X organization We School leading Indiana diabetes. tablets and have to University advancing are the trial II changing breakthroughs with of
with healthcare income lost are Americans in diabetes and realized living X $XX annually. United million Type is and X there a States approximately expenditure the diabetes X.XX billion Type Approximately associated
one-third in the than control Type target Moreover, blood are U.S. of less consistently achieving levels. people X glucose with diabetes
We forward along of II the to with with and University for trial this better JDRF Phase to School options population. treatment provide are Medicine move Indiana excited patient
In Phase I programs starting. we will development, be that we have three
First, cancer. in cell Eflornithine sachets KEYTRUDA evaluated of population will combination with STKXX non-small be in the lung mutation
bioinformatic non-cell role lung analysis in checkpoint poorly inhibitors polyamine STKXX that to play resistance mutant pathways suggests a responds may immunotherapy. and metabolic in alterations cancer to the
expression well anti-PD-X cytotoxic T tumor-specific models, PD-X tumor improves by T as increasing tumor-associated CDX-positive of on Eflornithine increased efficacy preclinical treatment cells. In population, cell as
on I starting is relationship and forward as The portion will to first proof-of-concept system. we funded be Phase look immune the and trial polyamine fully focused this clinical it between the trial the
If other inhibitor as is it immunotherapies tumors, combining of the for improve this trial CAR well therapy such positive, rates. in as possibility the with with a T opens possibility as checkpoint combining other response to
which Phase to second on first ivospemin the will I Our in cancer XXXX platinum-resistant focus half scheduled begin the program, population. ovarian of is of in the evaluation
this of John collaborated Hopkins reminder, we identify to Medicine School have indication. As with University a
survival ivospemin immune Additionally, cancer with overall on was prolonged tumor and mice ovarian competent a decrease of a significantly the injected presented in burden. with poster and showed treatment VDIDX-positive
Cancer a titled mature Potential Expanded Molecular Modulator Analogue The in the Metabolism as and Polyamine published of was International SBP-XXX the of Therapeutic. data later Journal Sciences Polyamine of
survival in median highlighted that XX% of vitro an a publication viability cancer strong ovarian The in in SBP-XXX VDIDX-positive cancer determined model. a cell across resulting with that in reduction increase broad ovarian cellular studies mouse viability, in reduced types range exceptionally adenocarcinoma the
initiate titled for the XXth AACR combination abstract We of which Efficacy our with in meeting, Research Evaluating or for ovarian an SBP-XXX efforts cancer the recently presentation program. announced Association American is Analogue poster acceptance the Ivospemin, occurring of at Clinical supports data April clinical ovarian year. XXth The Spermine the this the through cancer chemotherapy in to
completed preclinical have investigator necessary work to the begin cancer initiated we neoadjuvant a pancreatic trial. Lastly,
We leaders the year. approvals finalize this protocol with the institutional opinion in necessary half and the obtain open first the this to trial are of working to key
I a we as this the development execute of to early we the lung a finally, anticipate continue inform the we metastatic half presentation ovarian open the year in Phase the end, to our portion of work, the poster I non-small of of pancreatic To the neoadjuvant II futility mutation trial programs, hope year year, FAP programs year, ovarian trial, I in reduction cancer to open trial and cell the cancer in ASPIRE preclinical the recap data in the cell the Phase cancer SWOG trial STKXX the Phase XXXX. from the milestones in of the trial second which lung opening second AACR this will Type opening analysis cancer data half of cancer risk first the colon analysis X cancer III for trial, of Phase non-small final cell first-line of and lung interim half in trial, early which onset by Phase diabetes, this the non-small
we summary, In in year-to-date. made QX and progress have tremendous
stockholder enhance executing our ahead value and move we milestones. as to against excited XXXX are by We in onwards
I over the financials. turn and Sue will it stop here to review to
